Last reviewed · How we verify
Matching placebo SC + Mometasone Furoate
Matching placebo SC + Mometasone Furoate is a Topical corticosteroid Biologic drug developed by AstraZeneca. It is currently in Phase 3 development for Inflammatory skin conditions (specific indication in phase 3 trial unknown).
Mometasone furoate is a topical corticosteroid that reduces inflammation by suppressing immune responses and inflammatory mediators in the skin.
Mometasone furoate is a topical corticosteroid that reduces inflammation by suppressing immune responses and inflammatory mediators in the skin. Used for Inflammatory skin conditions (specific indication in phase 3 trial unknown).
At a glance
| Generic name | Matching placebo SC + Mometasone Furoate |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Biologic |
| Therapeutic area | Dermatology / Immunology |
| Phase | Phase 3 |
Mechanism of action
Mometasone furoate binds to glucocorticoid receptors in inflammatory cells, inhibiting the production of pro-inflammatory cytokines and mediators. This reduces vasodilation, edema, and immune cell infiltration at the site of application. The subcutaneous placebo control in this trial design allows for assessment of mometasone's efficacy independent of injection-related effects.
Approved indications
- Inflammatory skin conditions (specific indication in phase 3 trial unknown)
Common side effects
- Local skin atrophy
- Skin irritation or burning
- Folliculitis
- Systemic corticosteroid absorption effects
Key clinical trials
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps (PHASE2)
- Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis (PHASE3)
- Effect of Mepolizumab in Severe Bilateral Nasal Polyps (PHASE3)
- Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matching placebo SC + Mometasone Furoate CI brief — competitive landscape report
- Matching placebo SC + Mometasone Furoate updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Matching placebo SC + Mometasone Furoate
What is Matching placebo SC + Mometasone Furoate?
How does Matching placebo SC + Mometasone Furoate work?
What is Matching placebo SC + Mometasone Furoate used for?
Who makes Matching placebo SC + Mometasone Furoate?
What drug class is Matching placebo SC + Mometasone Furoate in?
What development phase is Matching placebo SC + Mometasone Furoate in?
What are the side effects of Matching placebo SC + Mometasone Furoate?
What does Matching placebo SC + Mometasone Furoate target?
Related
- Drug class: All Topical corticosteroid drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Dermatology / Immunology
- Indication: Drugs for Inflammatory skin conditions (specific indication in phase 3 trial unknown)
- Compare: Matching placebo SC + Mometasone Furoate vs similar drugs
- Pricing: Matching placebo SC + Mometasone Furoate cost, discount & access